Low-molecular-weight protein (LMP)2/LMP7 abnormality underlies the downregulation of human leukocyte antigen class I antigen in a hepatocellular carcinoma cell line

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1155-1161

  Shen, Yu Qing ^a   Zhang, Jian Qiong ^a   Xia, Mei ^a   Miao, Feng Qing ^a   Shan, Xiang Nian ^a   Xie, Wei ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Antigen presentation; Hepatocellular carcinoma; Human leukocyte antigens; Immunoproteasome; Interferon

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; LOW MOLECULAR WEIGHT PROTEIN 2; LOW MOLECULAR WEIGHT PROTEIN 7; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 34347401510     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04421.x     Document Type: Article

References (29)

1. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today 1995 16 : 487 94.
2. Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J. Med. 2003 52 : 220 9.
3. Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 2003 195 : 346 55.
4. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J. Clin. Invest. 1993 91 : 684 92.
5. Lassam N, Jay G. Suppression of MHC class I RNA in highly oncogenic cells occurs at the level of transcription initiation. J. Immunol. 1989 143 : 3792 7.
6. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 2000 21 : 455 64.
7. Loukissa A, Cardozo C, Altschuller-Felberg C, Nelson JE. Control of LMP7 expression in human endothelial cells by cytokines regulating cellular and humoral immunity. Cytokine 2000 12 : 1326 30.
8. Tanaka K, Tanahashi N, Tsurumi C, Yokota KY, Shimbara N. Proteasomes and antigen processing. Adv. Immunol. 1997 64 : 1 38.
9. van Endert PM. Genes regulating MHC class I processing antigen. Curr. Opin. Immunol. 1999 11 : 82 8.
10. Dissemond J, Goette P, Moers J et al. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res. 2003 13 : 371 7.
11. Seliger B, Atkins D, Bock M et al. Characterization of human lymphocyte antigen class I antigen processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter associated with antigen-processing down-regulation. Clin. Cancer Res. 2003 9 : 1721 7.
12. Matsui M, Machida S, Itani-Yohda T, Akatsuka T. Downregulation of the proteasome subunits, transporter, and antigen presentation in hepatocellular carcinoma, and their restoration by interferon-γ. J. Gastroenterol. Hepatol. 2002 17 : 897 907.
13. Fujiwara K, Higashi T, Nouso K et al. Decreased expression of B7 costimulatory molecules and major histocompatibility complex class-I in human hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2004 19 : 1121 7.
14. Matsui M, Ikeda M, Akatsuka T. High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem. Biophys. Res. Commun. 2001 280 : 1008 14.
15. Vitale M, Rezzani R, Rodella L et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998 58 : 737 42.
16. Topalian SL. MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy. Curr. Opin. Immunol. 1994 6 : 741 54.
17. Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 1994 179 : 335 40.
18. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 1994 145 : 505 9.
19. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 1993 177 : 265 72.
20. Singal DP, Ye M, Ni J, Snider DP. Markedly decreased expression of TAP1 and LMP2 genes in HLA class I-deficient human tumor cell lines. Immunol. Lett. 1996 50 : 149 54.
21. Momburg F, Degener T, Bacchus E, Moldenhauer G, Hammerling GJ, Moller P. Loss of HLA-A,B,C and denovo expression of HLA-D in colorectal cancer. Int. J. Cancer 1986 37 : 179 84.
22. Arnold D, Driscoll J, Androlewicz M, Hughes E, Cresswell P, Spies T. Proteasome subunits encoded in the MHC are not generally required for the processing of peptides bound by MHC class I molecules. Nature 1992 360 : 171 4.
23. Yewdell J, Lapham C, Bacik I, Spies T, Bennik J. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J. Immunol. 1994 152 : 1163 70.
24. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class I MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 1996 183 : 499 514.
25. Gaczynska M, Rock KL, Spies T, Goldberg AL. Peptidase activities of proteasomes are differentially regulated by the major histocompatibility complex-encoded genes for LMP2 and LMP7. Proc. Natl Acad. Sci. USA 1994 91 : 9213 17.
26. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992 15 : 948 63.
27. Kobayashi Y, Higashi T, Nouso K et al. Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. J. Hepatol. 2000 32 : 612 17.
28. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC, Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci. 1993 690 : 42 9.
29. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by denovo expression of H-2K antigens following H-2 gene transfection. Nature 1985 315 : 301 5.